

Supplemental figure S1: GFP expression in cardiomyocytes did not alter cardiac performance. HP, SI, DI, FS, and AI of model flies expressing or not GFP in cardiomyocytes were not significantly different. (n used was between 24 and 32). ***p<0.001, **p<0.01, *p<0.05, ns= not significant (Student´s t-test)



Supplemental figure S2: Daunorubicin did not modify MBNL1 or DMPK expression levels in human DM1 myoblasts. Immunoblotting against MBNL1 and ß-Actin of DM1 myoblasts cell lysate upon Daunorubicin treatment at 0.3, 1, 3 and 10 µM in DMSO for 24 h. (B) Quantitative RT-qPCR of DMPK and RPLP0 mRNAs of DM1 myoblasts total RNA upon Daunorubicin treatment at 0.3, 1, 3 and 10 µM in DMSO for 24 hours.



Supplemental figure S3: Daunorubicin did neither modify survival nor Mbl-dependent splicing in control flies expressing GFP. (A) Survival curves of control flies fed with DMSO (D) or Daunorubicin (Dauno) were identical. (B) qRT-PCR results of *Serca* exon 13 expression relative to *Rp49* confirmed that Daunorubicin did not influence this splicing pattern. The histograms show the mean±SEM. ns- not significant. (C) Semiquantitative RT-PCR to assess inclusion of *Fhos* exon 16′ in control flies fed with DMSO or Daunorubicin. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$ (Student's t-test).